Clinical Trials Directory

Trials / Completed

CompletedNCT02610270

Erythrocyte Omega-3 Fatty Acid Content in Elite Athletes

Erythrocyte Omega-3 Fatty Acid Content in Elite Athletes in Response to Omega-3 Supplementation: A Dose-Response

Status
Completed
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
24 (actual)
Sponsor
Centre d'Alt Rendiment · Academic / Other
Sex
All
Age
Healthy volunteers
Accepted

Summary

A suitable concentration of omega-3 fatty acids in relation to omega 6 is considered necessary for a good cell function and prevention of various inflammatory processes. Diet and supplementation are the fundamental procedures to achieve the reference values for several years. Athletes are individuals under physical stress and higher tissue restoration, while maintaining adequate diets they show, as the rest of humans, lower than desired levels. In the present study the investigators aims to determine the modification of those levels by the administration of two different doses of a given product, keeping the same model of diet and physical and competition.

Detailed description

The study aims to assess concentrations of the different fatty acids in the erythrocyte membrane before and after administration of a compound with high quality omega3 (EPA and DHA) in two different doses, compared with control group . The period of evaluation and management is four months, one month for the proposed renewal of red blood cells. The composition of the diet, the sports calendar, caloric expenditure and level of training is determined. During the study process it is excluded subjects with injuries or disease processes and ensure that no one take any supplement or modify workouts or diet.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENT2 Gums760 mg DHA
DIETARY_SUPPLEMENT3 Gums1140 mg DHA

Timeline

Start date
2014-06-01
Primary completion
2015-01-01
Completion
2015-04-01
First posted
2015-11-20
Last updated
2015-11-20

Source: ClinicalTrials.gov record NCT02610270. Inclusion in this directory is not an endorsement.